PDCD1 and neoplasm: Couple PD-1 blockade with spatially restricted IL-2Rβγ agonism on PD-1+ stem-like CD8+ T cells, potentially re-inflaming poorly infiltrated tumors and reshaping T-cell states more deeply than PD-1 alone;Masked PD-L1-binding domain designed to be unmasked by tumor-associated proteases, aiming to concentrate functional antibody activity in the TME and allow higher local occupancy with fewer systemic irAEs than unmasked PD-1/PD-L1 mAbs